Nicholas Jacobus

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

The change was driven by strong sales of Skyrizi and Rinvoq, and showcases robust growth and innovation in its portfolio.

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership with Walmart to launch retail pickup for its direct-to-consumer Zepbound program, and the FDA’s new draft guidance aimed at streamlining biosimilar development.

Novo Nordisk proposes a $9 billion acquisition of Metsera, prompting responses from both Metsera and Pfizer amid ongoing merger discussions.

Eli Lilly invests $1.2 billion in Puerto Rico to enhance manufacturing capabilities, creating jobs and integrating advanced technologies for oral medicines.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s partnership with NVIDIA to develop an AI supercomputer for drug discovery, a surge in biotech funding rounds and public offerings, and the FDA approval of Merck’s Winrevair for pulmonary arterial hypertension.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

The acquisition aims to enhance drug development capabilities and accelerate clinical research innovation.

Zepbound will be offered as part of the LillyDirect program and will be available to patients for pick-up in over 4600 Walmart Pharmacies nationwide.

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.

GSK secures exclusive rights to EMP-012, a promising treatment for COPD, enhancing its respiratory pipeline and addressing unmet medical needs.

Investments surge in the pharmaceutical sector as companies like Zag Bio and Hemab Therapeutics advance innovative treatments for rare diseases.

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.

Organon faces leadership changes as CEO Kevin Ali resigns amid an investigation into improper sales practices involving Nexplanon.

GSK secures exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment options for patients.

Novartis acquires Avidity Biosciences to enhance its RNA therapeutics pipeline, targeting rare neuromuscular diseases with innovative therapies.

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new funding momentum across rare disease R&D, and Eli Lilly’s definitive agreement to acquire Aderum Biotechnologies.

GSK's Blenrep gains FDA approval, offering new hope for multiple myeloma patients with improved survival rates and community access.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and why clinical trial site satisfaction is becoming a key competitive differentiator for sponsors and CROs.

Pharma investments surge as companies like Summit Therapeutics and Elevara Medicines secure funding to advance innovative drug development and clinical trials.

The decision impacts hopes for preventing congenital infections, although the company is continuing other research initiatives.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.

Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.

Recent research shows mRNA COVID vaccines significantly enhance survival rates in cancer patients undergoing immunotherapy, potentially revolutionizing cancer treatment.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.